ARGX ARGENX SE — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$874.74

Period return

+47.72 (+5.77%)

Volume

252.9K

2026-07-21O $861.55 H $877.58 L $859.42 C $874.74MA5 $860.48MA20 $887.42MA60 $846.81MA120 $812.27

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 23.Highin 2 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 16.LowBUY2 months ago
Evercore ISI Group: Outperform
US analyst rating / recommendation change.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.07%
2026. 05. 08.LowBUY2 months ago
Guggenheim: Buy
US analyst rating / recommendation change.
2026. 05. 08.LowBUY2 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2026. 04. 03.LowBUY4 months ago
Oppenheimer: Outperform
US analyst rating / recommendation change.
2026. 03. 09.LowBUY4 months ago
Wedbush: Outperform
US analyst rating / recommendation change.
2026. 02. 28.LowBUY5 months ago
RBC Capital: Outperform
US analyst rating / recommendation change.
2026. 02. 28.LowBUY5 months ago
Wells Fargo: Overweight
US analyst rating / recommendation change.
2026. 02. 27.LowBUY5 months ago
Citizens: Market Outperform
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $1,031.73 · 22 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Sector: Healthcare
Industry

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	258,556	$217.43M	0.34%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	109,121	$79.69M	0.07%	—	New position

ARGENX SE아르젠엑스

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 16.	Evercore ISI Group	—	Maintain	Outperform → Outperform	—	Evercore ISI Group: Outperform
2026. 05. 08.	Guggenheim	—	Maintain	Buy → Buy	—	Guggenheim: Buy
2026. 05. 08.	Wells Fargo	—	Maintain	Overweight → Overweight	—	Wells Fargo: Overweight
2026. 04. 03.	Oppenheimer	—	Maintain	Outperform → Outperform	—	Oppenheimer: Outperform
2026. 03. 09.	Wedbush	—	Maintain	Outperform → Outperform	—	Wedbush: Outperform
2026. 02. 28.	RBC Capital	—	Maintain	Outperform → Outperform	—	RBC Capital: Outperform